Login to Your Account



Tolerx Diabetes Candidate Falters in Phase III Trial

By Catherine Shaffer


Monday, March 14, 2011
The future of a $760 million partnership between Tolerx Inc. and GlaxoSmithKline plc has been cast into doubt as their investigational humanized anti-CD3 antibody missed its primary endpoint in a Phase III trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription